^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    epirubicin

    Company:
    Generic mfg.
    Drug class:
    Topoisomerase II inhibitor
    Related drugs:
    2d
    A Single-Arm Study on the Efficacy of Sequential Chemoradiotherapy Followed by Surgery in Adult Nasal and Paranasal Sinus Rhabdomyosarcoma (clinicaltrials.gov)
    P=N/A, N=43, Enrolling by invitation, Eye & ENT Hospital of Fudan University
    New trial
    |
    cisplatin • cyclophosphamide • epirubicin
    3d
    CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC (clinicaltrials.gov)
    P=N/A, N=324, Completed, First Affiliated Hospital, Sun Yat-Sen University
    New trial
    |
    sorafenib • epirubicin
    5d
    QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=30, Recruiting, Affiliated Hospital of Nantong University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative
    |
    carboplatin • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • epirubicin • Qibeian (iparomlimab/tuvonralimab)
    5d
    A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer (clinicaltrials.gov)
    P3, N=1800, Not yet recruiting, Shanghai JMT-Bio Inc.
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab) • doxorubicin hydrochloride • cyclophosphamide • epirubicin • anbenitamab (KN026)
    10d
    Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=72, Recruiting, Shandong Cancer Hospital and Institute | N=20 --> 72
    Enrollment change
    |
    Keytruda (pembrolizumab) • carboplatin • doxorubicin hydrochloride • AiRuiKa (camrelizumab) • albumin-bound paclitaxel • cyclophosphamide • epirubicin • Noxafil (posaconazole)
    15d
    A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC (clinicaltrials.gov)
    P3, N=236, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
    New P3 trial
    |
    gemcitabine • epirubicin • mitomycin • Pinorubin (pirarubicin) • SHR-1501
    16d
    EMEG-ECDD: Evaluation and Modeling of the Effect of G-CSF on the Evolution of Polynuclear Neutrophils During Dense Dose Epirubicin-Cyclophosphamide Regeneration (clinicaltrials.gov)
    P=N/A, N=97, Completed, Centre Georges Francois Leclerc | Recruiting --> Completed
    Trial completion
    |
    cyclophosphamide • epirubicin • Neulasta (pegfilgrastim) • Granocyte (lenograstim) • Neupogen (filgrastim)
    18d
    A clinical study of sac-TMT in people with breast cancer (MK-2870-032) (2024-520190-12-00)
    P2/3, N=565, Recruiting, Merck Sharp & Dohme LLC
    New P2/3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative • EGFR positive
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • doxorubicin hydrochloride • capecitabine • cyclophosphamide • epirubicin • Jiataile (sacituzumab tirumotecan)
    18d
    HCB-ONC002: HER2DX-guided diagnostic treatment For patients with HER2-positive early-stage breast cancer (2025-521040-37-00)
    P2/3, N=224, Recruiting, Fundacio De Recerca Clinic Barcelona-Institut DInvestigacions Biomediques August Pi I Sunyer
    New P2/3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HR negative
    |
    HER2DX
    |
    carboplatin • paclitaxel • docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • albumin-bound paclitaxel • cyclophosphamide • epirubicin • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    18d
    UC-BCG-2409/BIG 2402: Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer (2024-519655-28-00)
    P2/3, N=2270, Not yet recruiting, Unicancer
    New P2/3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • HR positive • HER-2 negative • HER-2 expression • ER negative
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay
    |
    paclitaxel • docetaxel • tamoxifen • doxorubicin hydrochloride • cyclophosphamide • letrozole • epirubicin • anastrozole • exemestane • triptorelin • goserelin acetate • leuprolide acetate for depot suspension
    18d
    UC-BCG-2501: NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early breast cancer treated with Ribociclib (LEE-011) innthe adjuvant setting (2025-520979-13-00)
    P2/3, N=3306, Recruiting, Unicancer
    New P2/3 trial • Head-to-Head
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    paclitaxel • docetaxel • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • Kisqali (ribociclib) • letrozole • epirubicin • anastrozole • exemestane • triptorelin • goserelin acetate • leuprolide acetate for depot suspension
    18d
    TARMAC: Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=85, Recruiting, University of Chicago | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    carboplatin • docetaxel • capecitabine • cyclophosphamide • epirubicin